Business
BioVersys Announces BV100 Phase 3 Initiation and Provides a Business Update
Ad hoc announcement pursuant to Art. 53LR BASEL, Switzerland, Dec. 11, 2025 (GLOBE NEWSWIRE) -- BV100 Phase 3 in Ventilator Associated Bacterial Pneumonia initiated with first country submission completed and first patients to be dosed in the coming months – Phase 3 read-out expected in H2 2027Significant value inflection points achieved in 2025 including: Successful IPO on SIX Swiss Exchange extending cash runway to 2028, Strong BV 100 Phase 2 data generated in VABP, Global Research Collaborati
About this update from Shionogi & Co., Ltd.
[{"type":"image","alt":"BioVersys","displaySize":"","headline":null,"caption":"BioVersys","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":65,"url":"https://media.zenfs.com/en/globenewswire.com/c1af1ca0425507c351838a72eb663c47"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_Zo6ExiGAEwq5bzAtMXIVw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkxO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/c1af1ca0425507c351838a72eb663c47","width":300,"height":65},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/_Zo6ExiGAEwq5bzAtMXIVw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkxO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/c1af1ca0425507c351838a72eb663c47","width":300,"height":65}},"lazy":false},{"type":"text","content":"Ad hoc announcement pursuant to Art. 53LR","length":41,"tagName":"p"},{"type":"text","content":"BASEL, Switzerland, Dec. 11, 2025 (GLOBE NEWSWIRE) -- ","length":53,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"BV100 Phase 3 in Ventilator Associated Bacterial Pneumonia initiated with first country submission completed and first patients to be dosed in the coming months – Phase 3 read-out expected in H2 2027","length":199,"tagName":"p"}]},{"val":[{"type":"text","content":"Significant value inflection points achieved in 2025 including: Successful IPO on SIX Swiss Exchange extending cash runway to 2028, Strong BV 100 Phase 2 data generated in VABP, Global Research Collaboration with Shionogi for BV500, alpibectir progressed to Phase 2 trial in pulmonary TB, and BV100 selection by ADVANCE-ID for upcoming Phase 2b, mostly financed by Wellcome","length":373,"tagName":"p"}]},{"val":[{"type":"text","content":"Strong news flow expected in 2026 including: 1st DSMB review for BV100 Phase 3, Interim data read-out for BV100 Phase 2b and Read-out of Phase 2 alpibectir in pulmonary tuberculosis by partner GSK","length":201,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":773,"olType":false},{"type":"text","content":"BioVersys AG, a multi-asset, late-stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant ("MDR") bacteria, announced today the initiation of its lead asset BV100 Phase 3 clinical program and provides a business update summarizing the Comp...